PNC Financial Services Group
SRPT icon

PNC Financial Services Group’s Sarepta Therapeutics SRPT Stock Holding History

PNC Financial Services Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80K Sell
4,453
-4,298
-49% -$81.3K ﹤0.01% 3074
2026
Q1 		$190K Buy
8,751
+636
+8% +$12.3K ﹤0.01% 2357
2025
Q4 		$175K Buy
8,115
+1,037
+15% +$21.9K ﹤0.01% 2400
2025
Q3 		$136K Buy
7,078
+3,299
+87% +$58.8K ﹤0.01% 2585
2025
Q2 		$64.6K Buy
3,779
+1,444
+62% +$61.6K ﹤0.01% 2971
2025
Q1 		$149K Sell
2,335
-556
-19% -$58.5K ﹤0.01% 2390
2024
Q4 		$352K Buy
2,891
+145
+5% +$17.8K ﹤0.01% 1798
2024
Q3 		$343K Sell
2,746
-433
-14% -$59.9K ﹤0.01% 1801
2024
Q2 		$502K Buy
3,179
+1,773
+126% +$228K ﹤0.01% 1484
2024
Q1 		$182K Sell
1,406
-183
-12% -$22.4K ﹤0.01% 2247
2023
Q4 		$153K Sell
1,589
-246
-13% -$23.6K ﹤0.01% 2342
2023
Q3 		$222K Sell
1,835
-1,012
-36% -$114K ﹤0.01% 2041
2023
Q2 		$326K Sell
2,847
-177
-6% -$22.8K ﹤0.01% 1855
2023
Q1 		$417K Sell
3,024
-295
-9% -$38.3K ﹤0.01% 1672
2022
Q4 		$430K Sell
3,319
-2,470
-43% -$286K ﹤0.01% 1626
2022
Q3 		$641K Buy
5,789
+244
+4% +$24.6K ﹤0.01% 1371
2022
Q2 		$416K Sell
5,545
-239
-4% -$17.6K ﹤0.01% 1649
2022
Q1 		$452K Buy
5,784
+3,783
+189% +$290K ﹤0.01% 1730
2021
Q4 		$180K Buy
2,001
+588
+42% +$50.3K ﹤0.01% 2316
2021
Q3 		$130K Buy
1,413
+395
+39% +$30.4K ﹤0.01% 2465
2021
Q2 		$79K Buy
1,018
+51
+5% +$3.87K ﹤0.01% 2793
2021
Q1 		$73K Sell
967
-491
-34% -$45.3K ﹤0.01% 2761
2020
Q4 		$248K Buy
1,458
+377
+35% +$55.9K ﹤0.01% 1931
2020
Q3 		$151K Buy
1,081
+600
+125% +$91.2K ﹤0.01% 2083
2020
Q2 		$77K Sell
481
-18,582
-97% -$2.53M ﹤0.01% 2499
2020
Q1 		$1.86M Sell
19,063
-413
-2% -$47.2K ﹤0.01% 752
2019
Q4 		$2.51M Sell
19,476
-11,072
-36% -$1.12M ﹤0.01% 750
2019
Q3 		$2.3M Sell
30,548
-10,036
-25% -$1.19M ﹤0.01% 919
2019
Q2 		$6.17M Sell
40,584
-26,631
-40% -$3.24M 0.01% 640
2019
Q1 		$8.01M Sell
67,215
-13,458
-17% -$1.73M 0.01% 572
2018
Q4 		$8.8M Sell
80,673
-24,316
-23% -$3.04M 0.01% 520
2018
Q3 		$17M Sell
104,989
-4,739
-4% -$648K 0.02% 427
2018
Q2 		$14.5M Sell
109,728
-7,260
-6% -$685K 0.01% 452
2018
Q1 		$8.67M Sell
116,988
-17,326
-13% -$1.16M 0.01% 563
2017
Q4 		$7.47M Sell
134,314
-28,607
-18% -$1.52M 0.01% 594
2017
Q3 		$7.39M Buy
162,921
+144,561
+787% +$5.78M 0.01% 577
2017
Q2 		$618K Buy
18,360
+13,694
+293% +$446K ﹤0.01% 1508
2017
Q1 		$138K Buy
4,666
+2,800
+150% +$86.7K ﹤0.01% 2316
2016
Q4 		$51K Sell
1,866
-300
-14% -$12K ﹤0.01% 2828
2016
Q3 		$132K Sell
2,166
-4,257
-66% -$129K ﹤0.01% 2322
2016
Q2 		$123K Sell
6,423
-2,003
-24% -$37.1K ﹤0.01% 2362
2016
Q1 		$164K Sell
8,426
-2,891
-26% -$50.5K ﹤0.01% 2235
2015
Q4 		$438K Buy
11,317
+3,300
+41% +$107K ﹤0.01% 1599
2015
Q3 		$258K Sell
8,017
-392
-5% -$13.3K ﹤0.01% 1962
2015
Q2 		$256K Buy
8,409
+99
+1% +$2.02K ﹤0.01% 2054
2015
Q1 		$111K Buy
8,310
+800
+11% +$10.7K ﹤0.01% 2620
2014
Q4 		$108K Sell
7,510
-943
-11% -$16K ﹤0.01% 2431
2014
Q3 		$178K Buy
8,453
+653
+8% +$14.7K ﹤0.01% 2063
2014
Q2 		$232K Buy
7,800
+200
+3% +$6.32K ﹤0.01% 1830
2014
Q1 		$184K Buy
7,600
+400
+6% +$10.2K ﹤0.01% 1933
2013
Q4 		$146K Sell
7,200
-4,000
-36% -$119K ﹤0.01% 2013
2013
Q3 		$529K Hold
11,200
– – ﹤0.01% 1317
2013
Q2 		$426K Buy
+11,200
New +$401K ﹤0.01% 1370

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PNC Financial Services Group's SRPT Position: Q2 2026 in Review

PNC Financial Services Group reduced its Sarepta Therapeutics (SRPT) stake by 49% in Q2 2026, selling an estimated $81.3K and leaving 4,453 shares worth $80K. The position accounts for ﹤0.01% of the portfolio, ranked #3074.

PNC Financial Services Group first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $17M in Q3 2018. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • PNC Financial Services Group held 4,453 shares of Sarepta Therapeutics worth $80K as of Q2 2026.
  • PNC Financial Services Group sold 4,298 Sarepta Therapeutics shares in Q2 2026, an estimated $81.3K.
  • Sarepta Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3074 holding.
  • PNC Financial Services Group first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • PNC Financial Services Group's Sarepta Therapeutics position peaked at $17M in Q3 2018.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.